Cotempla XR-ODT Tablets(Methylphenidate 哌醋甲酯缓释口服崩解片)
2017-11-09 09:57:20 作者: 新特药房 来源: 互联网 浏览次数: 0 文字大小:【 大】【 中】【 小】
简介:美国FDA批准Cotempla XR-ODT为第一个也是唯一的用于治疗注意力缺陷/多动症近日,美国食品和药物管理局(FDA)批准了第一个也是唯一的哌醋甲酯缓释口服崩解片剂Cotempla XR-ODT,用于治疗注意力缺陷/多动症(ADH ... 美国FDA批准Cotempla XR-ODT为第一个也是唯一的用于治疗注意力缺陷/多动症 近日,美国食品和药物管理局(FDA)批准了第一个也是唯一的哌醋甲酯缓释口服崩解片剂Cotempla XR-ODT,用于治疗注意力缺陷/多动症(ADHD) 6至17岁的患者。 适应症: Cotempla XR-ODT是一种中枢神经系统(CNS)兴奋剂,用于治疗6至17岁儿童ADHD。 剂量/给药:6至17岁的儿科患者建议起始剂量为17.3毫克,每天早晨口服一次。剂量可以每周增加8.6mg至17.3mg每天增加。不建议每日剂量高于51.8毫克。建议患者持续食用或不食用Cotempla XR-ODT。 不良反应: 根据其他哌甲酯产品的累积数据,最常见的(安慰剂的5%和2倍)不良反应是食欲下降,失眠,恶心,呕吐,消化不良,腹痛,体重减轻,焦虑,头晕,烦躁不安,影响不稳定,心动过速和血压升高。 Cotempla XR ODT(Methylphenidate Extended-Release Orally Disintegrating Tablets) COTEMPLA XR-ODT CII Generic Name and Formulations: Methylphenidate 8.6mg, 17.3mg, 25.9mg; ext-rel orally disintegrating tabs. Company: Neos Therapeutics Indications for COTEMPLA XR-ODT: Attention deficit hyperactivity disorder. Adults and Children: <6yrs: not established. Place tab on tongue and allow it to disintegrate; do not chew or crush. 6–17yrs: Individualize. Initially 17.3mg once daily in the AM. May titrate in increments of 8.6–17.3mg weekly; max 51.8mg daily. Discontinue if no improvement seen after dose adjustment over 1 month. Contraindications: During or within 14 days of MAOIs. Warnings/Precautions: High potential for abuse and dependence; monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing a manic episode prior to initiating. Consider discontinuing if psychotic/manic symptoms occur. Peripheral vasculopathy, including Raynaud’s phenomenon; monitor for digital changes. Monitor growth (in children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants. Interactions: See Contraindications. Concomitant gastric pH modulators (eg, omeprazole, famotidine, sodium bicarbonate): not recommended. Pharmacological Class: CNS stimulant. Adverse Reactions: Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, BP increased; priapism. Note: Register pregnant patients exposed to Cotempla XR-ODT by calling (866) 961-2388. Generic Availability: NO How Supplied: Blister pack—30 (5x6)
|